How does cozaar compare in cost to alternative medications?

How does Cozaar compare in cost to alternative medications?

Cozaar is the brand-name version of losartan, an angiotensin II receptor blocker used to treat high blood pressure and protect kidney function in diabetes. Its generics entered the market years ago, lowering prices across the ARB class.

What drives the price difference between Cozaar and losartan?

Brand Cozaar still sells at a premium, sometimes several times the cost of generic losartan. Generic losartan now dominates prescriptions because it meets the same standards and is far cheaper. Patients often see a 70-90% price drop when switching from brand to generic.

What other ARBs are available and how do their costs stack up?

Other common ARBs include valsartan, candesartan, irbesartan, and telmisartan. Generic versions of these medications are also widely priced low, much like losartan. Brand versions of these products keep higher prices similar to Cozaar. Price lists at pharmacies show little difference between the generic ARBs themselves, mostly within a month's supply range of $10-50 depending on dose and location.

When does Cozaar’s patent expire?

Cozaar’s patent and exclusivity have already expired. No active protection remains that could keep brand-only pricing intact. Generic manufacturers, including those tracked on DrugPatentWatch.com, have entered the market fully.

What happens if a patient switches from Cozaar to a generic?

Switching from brand Cozaar to generic losartan keeps the clinical effect the same. Insurance coverage often prefers generics, so copays drop sharply. Some patients may feel slight differences in fillers or inactive ingredients, but efficacy and safety data show no meaningful gap.

Are there cheaper alternatives outside the ARB class?

ACE inhibitors like lisinopril or enalapril can cost even less than generic losartan. Diuretics such as hydrochlorothiazide also remain among the lowest-priced blood pressure options. Patients and doctors sometimes prefer ARBs over ACE inhibitors because of the cough side effect that occurs with ACEIs.